Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Prostatic Diseases 1Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × Lutetium-177 × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡